– USA, MA – Solid Biosciences Inc. (NASDAQ: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today announced the appointment of Dr. Clare Kahn, Ph.D., and Dr. Georgia Keresty, Ph.D., M.P.H., to its Board of Directors, effective March 2, 2021.
“The addition of Clare and Georgia strengthens our Board by bringing new insights from their respective careers that can help guide the Company in realizing its mission,” said Board Chairman, Ian Smith. “On behalf of the entire board, I welcome them and look forward to working with them in continued support of the Company as it works to realize the differentiated potential of SGT-001 and additional opportunities to improve outcomes for patients with Duchenne.”
The company also announced that Erin Powers Brennan has joined as Chief Legal Officer and Dr. Joel Schneider, Ph.D., has been promoted to COO.
“Erin and Joel are two highly respected industry leaders who, in addition to their business acumen, share our passion for making a difference in the lives of patients with Duchenne and their families,” said Ilan Ganot, Co-Founder and CEO. “Joel was Solid’s first employee and has been an instrumental thought partner in all our corporate milestones and building our unique disease-focused business model. I’m also excited to welcome Erin, who brings more than 20 years of experience developing legal strategies across a broad range of complex, novel matters in the highly regulated healthcare and life sciences industry.”
About Dr. Clare Kahn
Dr. Kahn brings more than 30 years of experience in the pharmaceutical industry with a proven leadership record in strategic pharmaceutical development, registration, and product lifecycle management. Since retiring as head of Worldwide Regulatory Strategy for the Global Innovative Pharma Portfolio at Pfizer, she has advised multiple start-up and established companies. She serves as R&D Strategy Officer for X-VAX Technology Inc. and is a member of the Advisory Board of KBP Biosciences.
About Dr. Georgia Keresty
Dr. Keresty has an accomplished career of more than 30 years in the healthcare industry, having recently completed 3 years as R&D Chief Operating Officer of Takeda Pharmaceuticals and the prior 16 years as an executive at Johnson & Johnson. She serves on the boards of Aspen Technologies Inc. and Commissioning Agents Inc.
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001.
For more information : https://www.solidbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
